PMID- 16100293
OWN - NLM
STAT- MEDLINE
DCOM- 20060223
LR  - 20151119
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 45
IP  - 9
DP  - 2005 Sep
TI  - The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile 
      dysfunction.
PG  - 987-1003
AB  - Differences in the clinical pharmacology of the 3 currently available oral 
      phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are 
      largely determined by their clinical pharmacokinetics as well as their PDE 
      inhibitory activity profile. This review comparatively discusses the major 
      characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, 
      including bioavailability and rate of absorption, Biopharmaceutical 
      Classification System categorization, elimination mechanisms, and metabolic 
      profile including active metabolites, as well as the drug-drug interaction 
      potential and modification of pharmacokinetic properties under selected 
      physiologic and pathophysiologic conditions. The review is aimed at providing 
      comparative clinical pharmacology data to allow for scientifically rational, 
      evidence-based prescribing and dosing decisions regarding the clinical use of 
      these medications for the treatment of erectile dysfunction.
FAU - Gupta, Manish
AU  - Gupta M
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of 
      Tennessee Health Science Center, 874 Union Avenue, Suite 5p, Memphis, TN 38163, 
      USA.
FAU - Kovar, Andreas
AU  - Kovar A
FAU - Meibohm, Bernd
AU  - Meibohm B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Carbolines)
RN  - 0 (Imidazoles)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 0 (Triazines)
RN  - 5O8R96XMH7 (Vardenafil Dihydrochloride)
RN  - 742SXX0ICT (Tadalafil)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP3A)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
RN  - EC 3.1.4.35 (3',5'-Cyclic-GMP Phosphodiesterases)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
RN  - EC 3.1.4.35 (PDE5A protein, human)
SB  - IM
MH  - 3',5'-Cyclic-GMP Phosphodiesterases
MH  - Animals
MH  - Biological Availability
MH  - Carbolines/*pharmacokinetics
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5
MH  - Cytochrome P-450 CYP3A/metabolism
MH  - Drug Interactions
MH  - Erectile Dysfunction/*drug therapy/metabolism
MH  - Humans
MH  - Imidazoles/*pharmacokinetics
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Phosphodiesterase Inhibitors/*pharmacokinetics
MH  - Phosphoric Diester Hydrolases/metabolism
MH  - Piperazines/*pharmacokinetics
MH  - Purines
MH  - Sildenafil Citrate
MH  - Sulfones/pharmacokinetics
MH  - Tadalafil
MH  - Triazines/pharmacokinetics
MH  - Vardenafil Dihydrochloride
RF  - 66
EDAT- 2005/08/16 09:00
MHDA- 2006/02/24 09:00
CRDT- 2005/08/16 09:00
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2006/02/24 09:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
AID - 45/9/987 [pii]
AID - 10.1177/0091270005276847 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2005 Sep;45(9):987-1003. doi: 10.1177/0091270005276847.